The DOI matches its Crossref record; 317 of the 317 references it cites were found in a registry or an index.
Targeting hypoxia-inducible factors: therapeutic opportunities and challenges
Open accessAbstract
Hypoxia-inducible factors (HIFs) are highly conserved transcription factors that are crucial for adaptation of metazoans to limited oxygen availability. Recently, HIF activation and inhibition have emerged as therapeutic targets in various human diseases. Pharmacologically desirable effects of HIF activation include erythropoiesis stimulation, cellular metabolism optimization during hypoxia and adaptive responses during ischaemia and inflammation. By contrast, HIF inhibition has been explored as a therapy for various cancers, retinal neovascularization and pulmonary hypertension. This Review discusses the biochemical mechanisms that control HIF stabilization and the molecular strategies that can be exploited pharmacologically to activate or inhibit HIFs. In addition, we examine medical conditions that benefit from targeting HIFs, the potential side effects of HIF activation or inhibition and future challenges in this field. This Review discusses the mechanisms that regulate stabilization of hypoxia-inducible factors (HIFs), and the pharmacological strategies to activate or inhibit HIFs in diseases such as ischaemia, inflammation, cancer, retinal neovascularization and pulmonary hypertension.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Overall, adverse events with HIF-targeted agents are mechanistically informative and context-dependent, supporting patient selection, biomarker-guided monitoring, and agent-specific risk mitigation during prolonged therapy [37].”
From HIF inhibition: Current strategies and clinical challenges (2026) · cites this paper as [37]
The cited source says what the claim attributes to it.
In the citing paper
“The most frequent on-target toxicity with HIF-2 inhibitors (PT2385; belzutifan) is anemia from suppression of renal/hepatic erythropoietin.”
From HIF inhibition: Current strategies and clinical challenges (2026) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients
Locatelli, F., Fishbane, S. N., Block, G. A., & Macdougall, I. C. (2017) · American Journal of Nephrology · doi:10.1159/000455166 · Cited by 4,836
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735
Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
Forsythe, J. A., Jiang, B.-H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., & Semenza, G. L. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4604 · Cited by 3,981 · cited 1×
“Similarly, HIFαs are crucial for the induction of tumour growth factors, such as vascular endothelial growth factor (VEGF) 302,303 , via HIF2α in renal cell carcinoma 58 .”
Comprehensive molecular characterization of clear cell renal cell carcinoma
The Cancer Genome Atlas Research Network (2013) · Nature · doi:10.1038/nature12222 · Cited by 3,485
Ischemia and reperfusion—from mechanism to translation
Eltzschig, H. K., & Eckle, T. D. L. G. (2011) · Nature Medicine · doi:10.1038/nm.2507 · Cited by 3,468
Self-citationEpstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
Semenza, G. L., & Wang, G. L. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.12.5447 · Cited by 2,617
Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
Carmeliet, P., Dor, Y., Herbert, J.-M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., et al. (1998) · Nature · doi:10.1038/28867 · Cited by 2,502
Self-citationThe role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy
Muz, B., de la Puente, P., Azab, F., & Azab, A. K. (2015) · Hypoxia · doi:10.2147/hp.s93413 · Cited by 2,066 · cited 1×
“As the role of HIFs in cancer has been covered comprehensively by previous reviews 28,165,166 , we focus here on the therapeutic targeting of HIF1α in cancer and HIF2α in ccRCC and multiple paragangliomas, which have a more defined pathogenesis and are at the forefront of pharmacological targeting…”
Eltzschig, H. K., & Carmeliet, P. (2011) · New England Journal of Medicine · doi:10.1056/nejmra0910283 · Cited by 2,061
Self-citationTranscriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1.
Semenza, G., Roth, P. H., Fang, H. M., & Wang, G. L. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)31580-6 · Cited by 1,892
Jones, M., Ibels, L. S., Schenkel, B., & Zagari, M. J. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00450.x · Cited by 1,812
Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy
Semenza, G. L. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.01.005 · Cited by 1,514
General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia.
Wang, G. L., & Semenza, G. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.9.4304 · Cited by 1,468
Differential Roles of Hypoxia-Inducible Factor 1α (HIF-1α) and HIF-2α in Hypoxic Gene Regulation
Hu, C.-J., Wang, L.-Y., Chodosh, L. A., Keith, B., & Simon, M. C. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.24.9361-9374.2003 · Cited by 1,386
Tian, H., McKnight, S. L., & Russell, D. W. (1997) · Genes & Development · doi:10.1101/gad.11.1.72 · Cited by 1,351
Ohta, A., & Sitkovsky, M. V. (2001) · Nature · doi:10.1038/414916a · Cited by 1,336
Cellular Adaptation to Hypoxia through Hypoxia Inducible Factors and beyond
Lee, P., Chandel, N. S., & Simon, M. C. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0227-y · Cited by 1,272
HIF transcription factors, inflammation, and immunity
Palazon, A., Goldrath, A. W., Nizet, V., & Johnson, R. S. (2014) · Immunity · doi:10.1016/j.immuni.2014.09.008 · Cited by 1,195
Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1
Manalo, D. J., Rowan, A., Lavoie, T., Natarajan, L., Kelly, B. D., Ye, S. Q., Garcia, J. G. N., & Semenza, G. L. (2005) · Blood · doi:10.1182/blood-2004-07-2958 · Cited by 1,154
Kalantar‐Zadeh, K. (2017) · American Journal of Nephrology · doi:10.1159/000455387 · Cited by 1,149
Appelhoff, R. J., Tian, Y.-M., Raval, R. R., Turley, H., Harris, A. L., Pugh, C. W., Ratcliffe, P. J., & Gleadle, J. M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406026200 · Cited by 1,108
Hypoxia Regulates Vascular Endothelial Growth Factor Gene Expression in Endothelial Cells
Liu, Y., Cox, S. R., Morita, T., & Kourembanas, S. (1995) · Circulation Research · doi:10.1161/01.res.77.3.638 · Cited by 1,049
Integration of Oxygen Signaling at the Consensus HRE
Wenger, R. H., Stiehl, D. P., & Camenisch, G. (2005) · Science's STKE · doi:10.1126/stke.3062005re12 · Cited by 1,032
Oxygen Sensing, Homeostasis, and Disease
Semenza, G. L. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011165 · Cited by 1,014
Mechanisms of adverse effects of anti-VEGF therapy for cancer
Kamba, T., & McDonald, D. M. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603813 · Cited by 1,013
Semenza, G. L., Nejfelt, M. K., Chi, S. M., & Antonarakis, S. E. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.13.5680 · Cited by 990
Raval, R. R., Lau, K. W., Tran, M. G. B., Sowter, H. M., Mandriota, S. J., Li, J.-L., Pugh, C. W., Maxwell, P. H., Harris, A. L., & Ratcliffe, P. J. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.13.5675-5686.2005 · Cited by 940
Advances in Hypoxia-Inducible Factor Biology
Choudhry, H., & Harris, A. L. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.10.005 · Cited by 896
Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia.
Wang, G. L., & Semenza, G. L. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)80571-7 · Cited by 863
Transcriptional regulation by hypoxia inducible factors
Dengler, V. L., Galbraith, M. D., & Espinosa, J. M. (2013) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2013.838205 · Cited by 816
The role of HIF in immunity and inflammation
McGettrick, A. F., & O’Neill, L. A. J. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.08.002 · Cited by 768
Purinergic Signaling during Inflammation
Eltzschig, H. K., Sitkovsky, M. V., & Robson, S. C. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1205750 · Cited by 739
Self-citationBelzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease
Jonasch, E., Donskov, F., Iliopoulos, O., Rathmell, W. K., Narayan, V. K., Maughan, B. L., Oudard, S., Else, T., Maranchie, J. K., Welsh, S. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103425 · Cited by 714 · cited 6×
“In a phase II, open-label clinical trial, belzutifan provided clinical benefit in patients with ccRCC associated with VHL disease with an objective response rate of 49% 56 .”
InfluentialTargeting renal cell carcinoma with a HIF-2 antagonist
Chen, W., Hill, H., Christie, A., Kim, M. S., Holloman, E., Pavia-Jimenez, A., Homayoun, F., Ma, Y., Patel, N., Yell, P., et al. (2016) · Nature · doi:10.1038/nature19796 · Cited by 709
Synnestvedt, K., Furuta, G. T., Comerford, K. M., Louis, N. A., Karhausen, J., Eltzschig, H. K., Hansen, K. R., Thompson, L. F., & Colgan, S. P. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15337 · Cited by 706
Self-citationInhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression
Makino, Y., Cao, R., Svensson, K., Bertilsson, G., Asman, M., Tanaka, H., Cao, Y., Berkenstam, A., & Poellinger, L. (2001) · Nature · doi:10.1038/35107085 · Cited by 705
Synnestvedt, K., Furuta, G. T., Comerford, K. M., Louis, N., Karhausen, J., Eltzschig, H. K., Hansen, K. R., Thompson, L. F., & Colgan, S. P. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215337 · Cited by 660
Self-citationEpithelial hypoxia-inducible factor-1 is protective in murine experimental colitis
Karhausen, J., Furuta, G. T., Tomaszewski, J. E., Johnson, R. S., Colgan, S. P., & Haase, V. H. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200421086 · Cited by 655
Takeda, N., O'Dea, E. L., Doedens, A. L., Kim, J., Weidemann, A., Stockmann, C., Asagiri, M., Simon, M. C., Hoffmann, A., & Johnson, R. S. (2010) · Genes & Development · doi:10.1101/gad.1881410 · Cited by 646
Prabhakar, N. R., & Semenza, G. L. (2012) · Physiological Reviews · doi:10.1152/physrev.00030.2011 · Cited by 641
Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs)
Peyssonnaux, C., Zinkernagel, A. S., Schuepbach, R. A., Rankin, E., Vaulont, S., Haase, V. H., Nizet, V., & Johnson, R. S. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31370 · Cited by 639
Lee (2019) · doi:10.1038/s12276-019-0299-y · Cited by 635
Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis
Chen, N., Hao, C., Liu, B., Lin, H., Wang, C., Xing, C., Liang, X., Jiang, G., Liu, Z., Li, X., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901713 · Cited by 630
Hypoxia-inducible factors: cancer progression and clinical translation
Wicks, E. E., & Semenza, G. L. (2022) · Journal of Clinical Investigation · doi:10.1172/jci159839 · Cited by 626
Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth
Zhang, H., Qian, D. Z., Tan, Y. S., Lee, K., Gao, P., Ren, Y. R., Rey, S., Hammers, H., Chang, D., Pili, R., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809763105 · Cited by 624 · cited 3×
“Daily treatment with digoxin (2 mg kg −1 ) limits growth of P493-Myc cell line-derived tumour xenografts in vivo in murine models 141 .”
Kelly, B. D., Hackett, S. F., Hirota, K., Oshima, Y., Cai, Z., Berg-Dixon, S., Rowan, A., Yan, Z., Campochiaro, P. A., & Semenza, G. L. (2003) · Circulation Research · doi:10.1161/01.res.0000102937.50486.1b · Cited by 611
Purinergic Signaling during Inflammation
Eltzschig, H. K., Mv, S., & Robson, S. C. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1300259 · Cited by 609
Self-citationImmunological mechanisms of the antitumor effects of supplemental oxygenation
Hatfield, S. M., Kjaergaard, J., Lukashev, D., Schreiber, T. H., Belikoff, B., Abbott, R., Sethumadhavan, S., Philbrook, P., Ko, K., Cannici, R., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa1260 · Cited by 600
Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis
Chen, N., Hao, C., Peng, X., Lin, H., Yin, A., Hao, L., Tao, Y., Liang, X., Liu, Z., Xing, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813599 · Cited by 582
Clambey, E. T., McNamee, E. N., Westrich, J. A., Glover, L. E., Campbell, E. L., Jedlicka, P., de Zoeten, E. F., Cambier, J. C., Stenmark, K. R., Colgan, S. P., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1202366109 · Cited by 560 · cited 1×
“HIFs are also stabilized during inflammatory conditions or cancer 28–32 , partly owing to imbalances in metabolic supply and demand (including oxygen) 33,34 .”
Self-citationCrucial Role for Ecto-5′-Nucleotidase (CD73) in Vascular Leakage during Hypoxia
Thompson, L. F., Eltzschig, H. K., Ibla, J. C., Wiele, C. J. V. D., Resta, R., Morote–Garcia, J. C., & Colgan, S. P. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040915 · Cited by 544
Self-citationCircadian rhythm as a therapeutic target
Ruan, W., Yuan, X., & Eltzschig, H. K. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00109-w · Cited by 518
Self-citationThe effect of HIF on metabolism and immunity
Taylor, C. T., & Scholz, C. C. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00587-8 · Cited by 517
Iwai, K., Yamanaka, K., Kamura, T., Minato, N., Conaway, R. C., Conaway, J. W., Klausner, R. D., & Pause, A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.22.12436 · Cited by 508
Coordinated Adenine Nucleotide Phosphohydrolysis and Nucleoside Signaling in Posthypoxic Endothelium
Eltzschig, H. K., Ibla, J. C., Furuta, G. T., Leonard, M. O., Jacobson, K. A., Enjyoji, K., Robson, S. C., & Colgan, S. P. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030891 · Cited by 499
Self-citationCampbell, E. L., Bruyninckx, W. J., Kelly, C. J., Glover, L. E., McNamee, E. N., Bowers, B., Bayless, A. J., Scully, M. M., Saeedi, B. J., Golden‐Mason, L., et al. (2014) · Immunity · doi:10.1016/j.immuni.2013.11.020 · Cited by 481
Ardizzoni, A., Hansen, H., Dombernowsky, P., Gamucci, T., Kaplan, S., Postmus, P. E., Giaccone, G., Schaefer, B., Wanders, J., & Verweij, J. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.5.2090 · Cited by 480
Targeting the HIF2–VEGF axis in renal cell carcinoma
Choueiri, T. K., & Kaelin, W. G. (2020) · Nature Medicine · doi:10.1038/s41591-020-1093-z · Cited by 477
Aragonés, J., Schneider, M. A., Geyte, K. V., Fraisl, P., Dresselaers, T., Mazzone, M., Dirkx, R., Zacchigna, S., Lemieux, H., Jeoung, N. H., et al. (2008) · Nature Genetics · doi:10.1038/ng.2007.62 · Cited by 471
Self-citationStructural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1α
Freedman, S. J., Sun, Z., Poy, F., Kung, A. L., Livingston, D. M., Wagner, G., & Eck, M. J. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.082117899 · Cited by 457
(2002) · PubMed · Cited by 457
On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models
Cho, H., Du, X., Rizzi, J. P., Liberzon, E., Chakraborty, A. A., Gao, W., Carvo, I., Signoretti, S., Bruick, R. K., Josey, J. A., et al. (2016) · Nature · doi:10.1038/nature19795 · Cited by 451
Hypoxia-Inducible Factor-1 Is Central to Cardioprotection
Eckle, T. D. L. G., Köhler, D., Lehmann, R., Kasmi, K. C. E., & Eltzschig, H. K. (2008) · Circulation · doi:10.1161/circulationaha.107.758516 · Cited by 410
Self-citationThe Hydroxylase Inhibitor Dimethyloxalylglycine Is Protective in a Murine Model of Colitis
Cummins, E. P., Seeballuck, F., Keely, S. J., Mangan, N. E., Callanan, J. J., Fallon, P. G., & Taylor, C. T. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.10.012 · Cited by 407
Warnecke, C., Zaborowska, Z., Kurreck, J., Erdmann, V. A., Frei, U. A., Wiesener, M. S., & Eckardt, K. (2004) · The FASEB Journal · doi:10.1096/fj.04-1640fje · Cited by 404
Campochiaro, P. A. (2013) · Journal of Molecular Medicine · doi:10.1007/s00109-013-0993-5 · Cited by 400
Somatic HIF2A Gain-of-Function Mutations in Paraganglioma with Polycythemia
Zhuang, Z., Yang, C., Lorenzo, F., Merino, M., Fojo, T., Kebebew, E., Popovic, V., Stratakis, C. A., Prchal, J. T., & Pacak, K. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205119 · Cited by 397
Courtney, K. D., Infante, J. R., Lam, E. T., Figlin, R. A., Rini, B. I., Brugarolas, J., Zojwalla, N. J., Lowe, A. M., Wang, K., Wallace, E. M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.2627 · Cited by 393
A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment
Ohta, A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00109 · Cited by 385
Makino, Y., Kanopka, A., Wilson, W. J., Tanaka, H., & Poellinger, L. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200328200 · Cited by 376
Eltzschig, H. K., Thompson, L. F., Karhausen, J., Cotta, R. J., Ibla, J. C., Robson, S. C., & Colgan, S. P. (2004) · Blood · doi:10.1182/blood-2004-06-2066 · Cited by 371
Self-citationMucosal Protection by Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibition
Robinson, A., Keely, S., Karhausen, J., Gerich, M. E., Furuta, G. T., & Colgan, S. P. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.09.033 · Cited by 368
Targeting hypoxia signalling for the treatment of ischaemic and inflammatory diseases
Eltzschig, H. K., Bratton, D. L., & Colgan, S. P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4422 · Cited by 364
Self-citationHIF-1–dependent repression of equilibrative nucleoside transporter (ENT) in hypoxia
Eltzschig, H. K., ABDULLA, P. R., Hoffman, E., Hamilton, K. E., Daniels, D., Schönfeld, C., Löffler, M., Reyes, G., Duszenko, M., Karhausen, J., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050177 · Cited by 352
Self-citationPandey, A. K., Singhi, E. K., Arroyo, J. P., Ikizler, T. A., Gould, E. R., Brown, J. D., Beckman, J. A., Harrison, D. G., & Moslehi, J. J. (2017) · Hypertension · doi:10.1161/hypertensionaha.117.10271 · Cited by 346
Structural integration in hypoxia-inducible factors
Wu, D., Potluri, N., Lu, J., Kim, Y., & Rastinejad, F. (2015) · Nature · doi:10.1038/nature14883 · Cited by 346
Signalling hypoxia by HIF hydroxylases
Schofield, C. J., & Ratcliffe, P. J. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.08.111 · Cited by 343
A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma
Wallace, E. M., Rizzi, J. P., Han, G., Wehn, P. M., Cao, Z., Du, X., Cheng, T., Czerwinski, R. M., Dixon, D. D., Goggin, B. S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0473 · Cited by 336
Percy, M. J., Zhao, Q., Flores, A., Harrison, C., Lappin, T. R. J., Maxwell, P. H., McMullin, M. F., & Lee, F. S. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508423103 · Cited by 330
Inhibition of oxygen sensors as a therapeutic strategy for ischaemic and inflammatory disease
Fraisl, P., Aragonés, J., & Carmeliet, P. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2761 · Cited by 326
Self-citationOzaki, H., Yu, A. Y., Della, N. G., Ozaki, K., Luna, J. D., Yamada, H., Hackett, S. F., Okamoto, N., Zack, D. J., Semenza, G. L., et al. (1999) · PubMed · Cited by 323
Motzer, R. J., Escudier, B. J., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Plimack, E. R., Procopio, G., McDermott, D. F., et al. (2020) · Cancer · doi:10.1002/cncr.33033 · Cited by 317
Allosteric inhibition of hypoxia inducible factor-2 with small molecules
Scheuermann, T. H., Li, Q., Ma, H.-W., Key, J., Zhang, L., Chen, R., Garcia, J. A., Naidoo, J., Longgood, J., Frantz, D. E., et al. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1185 · Cited by 315
A Gain-of-Function Mutation in the HIF2A Gene in Familial Erythrocytosis
Percy, M. J., Furlow, P. W., Lucas, G. S., Li, X., Lappin, T. R. J., McMullin, M. F., & Lee, F. S. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa073123 · Cited by 314
Eckle, T., Hartmann, K., Bonney, S., Reithel, S., Mittelbronn, M., Walker, L. A., Lowes, B. D., Han, J., Borchers, C. H., Buttrick, P. M., et al. (2012) · Nature Medicine · doi:10.1038/nm.2728 · Cited by 314
Self-citationDifferential Dependence of Hypoxia-inducible Factors 1α and 2α on mTORC1 and mTORC2
Toschi, A., Lee, E., Gadir, N., Ohh, M., & Foster, D. A. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.c800170200 · Cited by 313
The physiological functions of iron regulatory proteins in iron homeostasis - an update
Zhang, D., Ghosh, M. C., & Rouault, T. A. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00124 · Cited by 310
Koh, M. Y., Spivak-Kroizman, T., Venturini, S., Welsh, S., Williams, R. R., Kirkpatrick, D. L., & Powis, G. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0463 · Cited by 309
HIF Inhibitors: Status of Current Clinical Development
Fallah, J., & Rini, B. I. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0752-z · Cited by 308
Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia
Kapitsinou, P. P., Liu, Q., Unger, T. L., Rha, J., Davidoff, O., Keith, B., Epstein, J. A., Moores, S. L., Erickson-Miller, C. L., & Haase, V. H. (2010) · Blood · doi:10.1182/blood-2010-02-270322 · Cited by 307
Choueiri, T. K., Bauer, T. M., Papadopoulos, K. P., Plimack, E. R., Merchan, J. R., McDermott, D. F., Michaelson, M. D., Appleman, L. J., Thamake, S., Perini, R. F., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01324-7 · Cited by 305
Topoisomerase I-Mediated Inhibition of Hypoxia-Inducible Factor 1
Rapisarda, A., Uranchimeg, B., Sordet, O., Pommier, Y., Shoemaker, R. H., & Melillo, G. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3139 · Cited by 301
Artificial ligand binding within the HIF2α PAS-B domain of the HIF2 transcription factor
Scheuermann, T. H., Tomchick, D. R., Machius, M., Guo, Y., Bruick, R. K., & Gardner, K. H. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808092106 · Cited by 301
Preconditional Activation of Hypoxia-Inducible Factors Ameliorates Ischemic Acute Renal Failure
Bernhardt, W. M., Accent]mpean, V. C. C., Kany, S., Diaeresis]rgensen, J.-S. J., Weidemann, A., Warnecke, C., Arend, M., Klaus, S. J., Diaeresis]nzler, V. G., Amann, K., et al. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005121302 · Cited by 299
Perioperative Acute Kidney Injury
Gumbert, S. D., Kork, F., Jackson, M. L., Vanga, N., Ghebremichael, S. J., Wang, C. Y., & Eltzschig, H. K. (2019) · Anesthesiology · doi:10.1097/aln.0000000000002968 · Cited by 299
Self-citationFeldman, D. R., Baum, M. S., Ginsberg, M. S., Hassoun, H., Flombaum, C. D., Velasco, S., Fischer, P., Ronnen, E. A., Ishill, N. M., Patil, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.0108 · Cited by 298
Provenzano, R., Besarab, A., Sun, C. H., Diamond, S. A., Durham, J. H., Cangiano, J. L., Aiello, J. R., Novak, J. E., Lee, T. T., Leong, R., et al. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06890615 · Cited by 297
Besarab, A., Provenzano, R., Hertel, J., Zabaneh, R. I., Klaus, S. J., Lee, T. T., Leong, R., Hemmerich, S., Yu, K.-H. P., & Neff, T. B. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv302 · Cited by 293
HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond
Maxwell, P. H., & Eckardt, K. (2015) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.193 · Cited by 288
Pharmacologic Targeting of Hypoxia-Inducible Factors
Semenza, G. L. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021637 · Cited by 288
HIF-1 mediates the Warburg effect in clear cell renal carcinoma
Semenza, G. L. (2007) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-007-9081-2 · Cited by 281
Welsh, S. J., Williams, R. R., Kirkpatrick, L., Paine-Murrieta, G. D., & Powis, G. (2004) · PubMed · Cited by 280
Hill, P., Shukla, D., Tran, M. G. B., Aragonés, J., Cook, H. T., Carmeliet, P., & Maxwell, P. H. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006090998 · Cited by 280
Self-citationThe human side of hypoxia‐inducible factor
Smith, T. G., Robbins, P. A., & Ratcliffe, P. J. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07029.x · Cited by 270
Provenzano, R., Besarab, A., Wright, S., Dua, S., Zeig, S., Nguyen, P., Poole, L., Saikali, K. G., Saha, G. C., Hemmerich, S., et al. (2016) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.12.020 · Cited by 267
Roxadustat: First Global Approval
Dhillon, S. (2019) · Drugs · doi:10.1007/s40265-019-01077-1 · Cited by 267
Taylor, M., Qu, A., Anderson, E. R., Matsubara, T., Martin, A., Gonzalez, F. J., & Shah, Y. M. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.03.007 · Cited by 265
Vadadustat in Patients with Anemia and Non–Dialysis-Dependent CKD
Chertow, G. M., Pérgola, P. E., Farag, Y. M. K., Agarwal, R., Arnold, S., Bako, G., Block, G. A., Burke, S. K., Castillo, F. P., Jardine, A. G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035938 · Cited by 261
Matsumoto, M., Makino, Y., Tanaka, T., Tanaka, H., Ishizaka, N., Noiri, E., Fujita, T., & Nangaku, M. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000074239.22357.06 · Cited by 256
Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis
Singh, A. K., Carroll, K., Perkovic, V., Solomon, S. D., Jha, V., Johansen, K. L., Lópes, R. D., Macdougall, I. C., Obrador, G. T., Waikar, S. S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2113379 · Cited by 256
The Asparaginyl Hydroxylase Factor Inhibiting HIF-1α Is an Essential Regulator of Metabolism
Zhang, N., Fu, Z., Linke, S., Chicher, J., Gorman, J. J., Visk, D., Haddad, G. G., Poellinger, L., Peet, D. J., Powell, F. L., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.03.001 · Cited by 255
Besarab, A., Chernyavskaya, E. A., Motylev, I., Shutov, E. V., Kumbar, L. M., Gurevich, K., Chan, D. T. M., Leong, R., Poole, L., Zhong, M., et al. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015030241 · Cited by 250
Semenza, G. L., Koury, S. T., Nejfelt, M. K., Gearhart, J. D., & Antonarakis, S. E. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.19.8725 · Cited by 248
Inflammation and Hypoxia: HIF and PHD Isoform Selectivity
Watts, E., & Walmsley, S. R. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.10.006 · Cited by 248
Molecular and cellular mechanisms of HIF prolyl hydroxylase inhibitors in clinical trials
Yeh, T., Leissing, T. M., Abboud, M. I., Thinnes, C. C., Atasoylu, O., Holt‐Martyn, J. P., Zhang, D., Tumber, A., Lippl, K., Lohans, C. T., et al. (2017) · Chemical Science · doi:10.1039/c7sc02103h · Cited by 247
A RNA antagonist of hypoxia-inducible factor-1α, EZN-2968, inhibits tumor cell growth
Greenberger, L. M., Horak, I. D., Filpula, D., Sapra, P., Westergaard, M., Frydenlund, H. F., Albæk, C., Schrøder, H., & Ørum, H. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0510 · Cited by 245
Welsh, S., Williams, R., Kirkpatrick, L., Paine-Murrieta, G., & Powis, G. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.233.3.3 · Cited by 240
Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis
Singh, A. K., Carroll, K., McMurray, J. J. V., Solomon, S. D., Jha, V., Johansen, K. L., Lópes, R. D., Macdougall, I. C., Obrador, G. T., Waikar, S. S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2113380 · Cited by 234
Hypoxia-inducible factor signaling in pulmonary hypertension
Pullamsetti, S. S., Mamazhakypov, A., Weissmann, N., Seeger, W., & Savai, R. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137558 · Cited by 234
Revised Definition of Pulmonary Hypertension and Approach to Management: A Clinical Primer
Maron, B. A. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.029024 · Cited by 229
Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis
Eckardt, K., Agarwal, R., Aswad, A., Awad, A., Block, G. A., Bacci, M. R., Farag, Y. M. K., Fishbane, S. N., Hubert, H., Jardine, A. G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2025956 · Cited by 222
Xu, R., Wang, K., Rizzi, J. P., Huang, H., Grina, J. A., Schlachter, S. T., Wang, B., Wehn, P. M., Yang, H., Dixon, D. D., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00719 · Cited by 220
Hypoxia and inflammation are two sides of the same coin
Bartels, K., Grenz, A., & Eltzschig, H. K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1318345110 · Cited by 218
Self-citationMcNEILL, L. A., HEWITSON, K. S., CLARIDGE, T. D., SEIBEL, J. F., HORSFALL, L. E., & SCHOFIELD, C. J. (2002) · Biochemical Journal · doi:10.1042/bj20021162 · Cited by 215
Ockaili, R. A., Natarajan, R., Salloum, F. N., Fisher, B. J., Jones, D. G., Fowler, A. A., & Kukreja, R. C. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00089.2005 · Cited by 214
HIF-1–dependent repression of adenosine kinase attenuates hypoxia-induced vascular leak
Morote–Garcia, J. C., Rosenberger, P., Kuhlicke, J., & Eltzschig, H. K. (2008) · Blood · doi:10.1182/blood-2007-11-126763 · Cited by 211
Self-citationRepression via the GATA box is essential for tissue-specific erythropoietin gene expression
Obara, N., Suzuki, N., Kim, K., Nagasawa, T., Imagawa, S., & Yamamoto, M. P. (2008) · Blood · doi:10.1182/blood-2007-10-115857 · Cited by 207
Haase, V. H. (2021) · Kidney International Supplements · doi:10.1016/j.kisu.2020.12.002 · Cited by 205
Tambuwala, M. M., Cummins, E. P., Lenihan, C. R., Kiss, J., Stauch, M., Scholz, C. C., Fraisl, P., Lasitschka, F., Mollenhauer, M., Saunders, S. P., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.06.068 · Cited by 204
Self-citationBartels, K., Karhausen, J., Clambey, E. T., Grenz, A., & Eltzschig, H. K. (2013) · Anesthesiology · doi:10.1097/aln.0000000000000022 · Cited by 196
Self-citationContemporary Use of Digoxin in the Management of Cardiovascular Disorders
Gheorghiade, M., van Veldhuisen, D. J., & Colucci, W. S. (2006) · Circulation · doi:10.1161/circulationaha.105.560110 · Cited by 194
Endothelial HIF-2 mediates protection and recovery from ischemic kidney injury
Kapitsinou, P. P., Sano, H., Michael, M., Kobayashi, H., Davidoff, O., Bian, A., Yao, B., Zhang, M.-Z., Harris, R. C., Duffy, K. J., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69073 · Cited by 192
Zimmer, M., Ebert, B. L., Neil, C., Brenner, K., Papaioannou, I., Melas, A., Tolliday, N., Lamb, J., Pantopoulos, K., Golub, T., et al. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.12.004 · Cited by 191
Tang, H., Babicheva, A., McDermott, K. M., Gu, Y., Ayon, R. J., Song, S., Wang, Z., Gupta, A., Zhou, T., Sun, X., et al. (2017) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00096.2017 · Cited by 190
Hypoxia-Inducible Factor Activators in Renal Anemia: Current Clinical Experience
Sanghani, N. S., & Haase, V. H. (2019) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2019.04.004 · Cited by 188
Courtney, K. D., Ma, Y., Diaz de Leon, A., Christie, A., Xie, Z., Woolford, L., Singla, N., Joyce, A., Hill, H., Madhuranthakam, A. J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1459 · Cited by 188
HIF2α–arginase axis is essential for the development of pulmonary hypertension
Cowburn, A. S., Crosby, A., Macías, D., Branco, C. M., Colaço, R., Southwood, M. R., Toshner, M. R., Alexander, L. E. C., Morrell, N. W., Chilvers, E. R., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1602978113 · Cited by 187
Rapisarda, A., Zalek, J., Hollingshead, M., Braunschweig, T., Uranchimeg, B., Bonomi, C. A., Borgel, S. D., Carter, J. P., Hewitt, S. M., Shoemaker, R. H., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2116 · Cited by 187
Miranda, E., Nordgren, I. K., Male, A. L., Lawrence, C. E., Hoakwie, F., Cuda, F., Court, W., Fox, K. R., Townsend, P. A., Packham, G. K., et al. (2013) · Journal of the American Chemical Society · doi:10.1021/ja402993u · Cited by 185
Protein Hydroxylation Catalyzed by 2-Oxoglutarate-dependent Oxygenases
Markolovic, S., Wilkins, S. E., & Schofield, C. J. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.r115.662627 · Cited by 181
Flamme, I., Oehme, F., Ellinghaus, P., Jeske, M., Keldenich, J., & Thuß, U. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111838 · Cited by 174
Erythropoietin mRNA Expression in Human Fetal and Neonatal Tissue
Dame, C., Fahnenstich, H., Freitag, P., Hofmann, D., Abdul‐Nour, T., Bartmann, P., & Fandrey, J. (1998) · Blood · doi:10.1182/blood.v92.9.3218.421k11_3218_3225 · Cited by 172
Endothelial Cell HIF-1α and HIF-2α Differentially Regulate Metastatic Success
Branco-Price, C., Zhang, N., Schnelle, M., Evans, C., Katschinski, D. M., Liao, D., Ellies, L., & Johnson, R. S. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.11.017 · Cited by 168
Hypoxia and Innate Immunity: Keeping Up with the HIFsters
Colgan, S. P., Furuta, G. T., & Taylor, C. T. (2020) · Annual Review of Immunology · doi:10.1146/annurev-immunol-100819-121537 · Cited by 167
HIF1A Reduces Acute Lung Injury by Optimizing Carbohydrate Metabolism in the Alveolar Epithelium
Eckle, T. D. L. G., Brodsky, K. S., Bonney, M., Packard, T. A., Han, J., Borchers, C. H., Mariani, T. J., Kominsky, D. J., Mittelbronn, M. G. A., & Eltzschig, H. K. (2013) · PLoS Biology · doi:10.1371/journal.pbio.1001665 · Cited by 166
Self-citationNatarajan, R., Salloum, F. N., Fisher, B. J., Kukreja, R. C., & Fowler, A. A. (2005) · Circulation Research · doi:10.1161/01.res.0000197816.63513.27 · Cited by 166
HIF‐prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism
Haase, V. H. (2017) · Hemodialysis International · doi:10.1111/hdi.12567 · Cited by 164
Dai, Z., Zhu, M. M., Peng, Y., Machireddy, N., Evans, C. E., Machado, R. F., Zhang, X., & Zhao, Y. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201710-2079oc · Cited by 164
Reactivation of hepatic EPO synthesis in mice after PHD loss
Minamishima, Y. A., & Kaelin, W. G. (2010) · Science · doi:10.1126/science.1192811 · Cited by 163
Ong, S., Lee, W. H., Theodorou, L., Kodo, K., Lim, S. Y., Shukla, D., Briston, T., Kiriakidis, S., Ashcroft, M. A., Davidson, S. M., et al. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvu172 · Cited by 160
Jeong, W., Rapisarda, A., Park, S. R., Kinders, R. J., Chen, A., Melillo, G., Turkbey, B., Steinberg, S. M., Choyke, P., Doroshow, J. H., et al. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2362-z · Cited by 159 · cited 1×
“The early effort to study HIF1A RNAi by ASO EZN-2968 in patients with refractory solid tumours was terminated prematurely owing to the loss of interest from the sponsoring agent 170 .”
HIF in the heart: development, metabolism, ischemia, and atherosclerosis
Knutson, A. K., Williams, A. L., Boisvert, W. A., & Shohet, R. V. (2021) · Journal of Clinical Investigation · doi:10.1172/jci137557 · Cited by 158
New Syndrome of Paraganglioma and Somatostatinoma Associated With Polycythemia
Pacák, K., Jochmanová, I., Prodanov, T., Yang, C., Merino, M. J., Fojo, T., Prchal, J. T., Tischler, A. S., Lechan, R. M., & Zhuang, Z. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.1912 · Cited by 157
Yang, C., Zhuang, Z., Fliedner, S. M. J., Shankavaram, U. T., Sun, M. G., Bullova, P., Zhu, R., ELKAHLOUN, A. G., Kourlas, P. J., Merino, M. J., et al. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1205-7 · Cited by 153
Bernhardt, W. M., Göttmann, U., Doyon, F., Buchholz, B., Câmpean, V., Schödel, J., Reisenbuechler, A., Klaus, S. J., Arend, M., Flippin, L. A., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903978106 · Cited by 150
Adenosine A 2A receptor is a unique angiogenic target of HIF-2α in pulmonary endothelial cells
Ahmad, A. M., Ahmad, S., Glover, L. E., Miller, S. M., Shannon, J. M., Guo, X., Franklin, W. A., Bridges, J. P., Schaack, J. B., Colgan, S. P., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0901326106 · Cited by 145
Hypoxia-independent activation of HIF-1 by enterobacteriaceae and their siderophores
Hartmann, H., Eltzschig, H. K., Wurz, H., Hantke, K., Rakin, A., Yazdi, A. S., Matteoli, G., Bohn, E., Autenrieth, I. B., Karhausen, J., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.12.008 · Cited by 143
Self-citationTwo transactivation mechanisms cooperate for the bulk of HIF‐1‐responsive gene expression
Kasper, L. H., Boussouar, F., Boyd, K. L., Xu, W., Biesen, M. A., Rehg, J. E., Baudino, T. A., Cleveland, J. L., & Brindle, P. K. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600846 · Cited by 140
The Genomics and Genetics of Oxygen Homeostasis
Semenza, G. L. (2020) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-111119-073356 · Cited by 139
HIF2α signaling inhibits adherens junctional disruption in acute lung injury
Gong, H., Rehman, J., Tang, H., Wary, K. K., Mittal, M., Chatturvedi, P., Zhao, Y., Komorova, Y. A., Vogel, S. M., & Malik, A. B. (2015) · Journal of Clinical Investigation · doi:10.1172/jci77701 · Cited by 136
mTOR inhibitors in renal cell carcinoma
Battelli, C., & Cho, D. C. (2011) · Therapy · doi:10.2217/thy.11.32 · Cited by 136
Taylor, C. T., & McElwain, J. C. (2010) · Physiology · doi:10.1152/physiol.00029.2010 · Cited by 135
Erythropoietin Action in Stress Response, Tissue Maintenance and Metabolism
Zhang, Y., Wang, L., Dey, S., Alnaeeli, M., Suresh, S., Rogers, H. M., Teng, R., & Noguchi, C. T. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms150610296 · Cited by 132
Schneider, M. A., Geyte, K. V., Fraisl, P., Kiss, J., Aragonés, J., Mazzone, M., Mairbäurl, H., Bock, K. D., Jeoung, N. H., Mollenhauer, M., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.09.057 · Cited by 131
Self-citationNwogu, J. I., Geenen, D., Bean, M., Brenner, M. C., Huang, X., & Buttrick, P. M. (2001) · Circulation · doi:10.1161/hc4301.097193 · Cited by 131
Renal erythropoietin-producing cells in health and disease
Souma, T., Suzuki, N., & Yamamoto, M. P. (2015) · Frontiers in Physiology · doi:10.3389/fphys.2015.00167 · Cited by 129
Xi, L., Taher, M. M., Yin, C., Salloum, F. N., & Kukreja, R. C. (2004) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00422.2004 · Cited by 129
Novel exon 12 mutations in the HIF2A gene associated with erythrocytosis
Percy, M. J., Beer, P. A., Campbell, G., Dekker, A. W., Green, A. R., Oscier, D., Rainey, M. G., van Wijk, R., Wood, M., Lappin, T. R. J., et al. (2008) · Blood · doi:10.1182/blood-2008-02-137703 · Cited by 127
Koeppen, M., Lee, J. W., Seo, S.-W., Brodsky, K. S., Kreth, S., Yang, I. V., Buttrick, P. M., Eckle, T. D. L. G., & Eltzschig, H. K. (2018) · Nature Communications · doi:10.1038/s41467-018-03105-2 · Cited by 126
Self-citationPoth, J. M., Brodsky, K. S., Ehrentraut, H., Grenz, A., & Eltzschig, H. K. (2012) · Journal of Molecular Medicine · doi:10.1007/s00109-012-0988-7 · Cited by 125
Self-citationEGF Receptor–Dependent YAP Activation Is Important for Renal Recovery from AKI
Chen, J., You, H., Li, Y., You, X., Qian, H., & Harris, R. C. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2017121272 · Cited by 124
Acute Respiratory Distress Syndrome
Williams, G. W., Berg, N. K., Reskallah, A., Yuan, X., & Eltzschig, H. K. (2020) · Anesthesiology · doi:10.1097/aln.0000000000003571 · Cited by 123
Self-citationWehn, P. M., Rizzi, J. P., Dixon, D. D., Grina, J. A., Schlachter, S. T., Wang, B., Xu, R., Yang, H., Du, X., Han, G., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01196 · Cited by 122
Yang, Y., Yu, X., Zhang, Y., Ding, G., Zhu, C., Huang, S., Jia, Z., & Zhang, A. (2018) · Clinical Science · doi:10.1042/cs20171625 · Cited by 122
Suppression of HIF2 signalling attenuates the initiation of hypoxia-induced pulmonary hypertension
Hu, C., Poth, J. M., Zhang, H., Flockton, A. R., Laux, A., Kumar, S., McKeon, B. A., Mouradian, G. C., Li, M., Riddle, S. R., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.00378-2019 · Cited by 121
CD146-HIF-1α hypoxic reprogramming drives vascular remodeling and pulmonary arterial hypertension
Luo, Y., Teng, X., Zhang, L., Chen, J., Liu, Z., Chen, X., Zhao, S., Yang, S., Feng, J., & Yan, X. (2019) · Nature Communications · doi:10.1038/s41467-019-11500-6 · Cited by 121
Pathophysiology of anemia and erythrocytosis
Hodges, V. M., Rainey, S., Lappin, T. R. J., & Maxwell, A. P. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.06.006 · Cited by 118
The hypoxia-adenosine link during inflammation
Bowser, J. L., Lee, J. W., Yuan, X., & Eltzschig, H. K. (2017) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00101.2017 · Cited by 118
Self-citationThe gut in iron homeostasis: role of HIF-2 under normal and pathological conditions
Mastrogiannaki, M., Matak, P., & Peyssonnaux, C. (2013) · Blood · doi:10.1182/blood-2012-11-427765 · Cited by 116
Attenuating myocardial ischemia by targeting A2B adenosine receptors
Eltzschig, H. K., Bonney, S. K., & Eckle, T. D. L. G. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.02.005 · Cited by 116
Self-citationHIF-α Prolyl Hydroxylase Inhibitors and Their Implications for Biomedicine: A Comprehensive Review
Hirota, K. (2021) · Biomedicines · doi:10.3390/biomedicines9050468 · Cited by 115
Okumura, C. Y. M., Hollands, A., Tran, D. N., Olson, J., Dahesh, S., von Köckritz-Blickwede, M., Thienphrapa, W., Corle, C., Jeung, S. N., Kotsakis, A., et al. (2012) · Journal of Molecular Medicine · doi:10.1007/s00109-012-0882-3 · Cited by 115
The last common ancestor of animals lacked the HIF pathway and respired in low-oxygen environments
Mills, D. B., Francis, W. R., Vargas, S., Larsen, M., Elemans, C. P., Canfield, D. E., & Wörheide, G. (2018) · eLife · doi:10.7554/elife.31176 · Cited by 114
Bidirectional modulation of HIF-2 activity through chemical ligands
Wu, D., Su, X., Lu, J.-P., Li, S., Hood, B. L., Vasile, S., Potluri, N., Diao, X., Kim, Y., Khorasanizadeh, S., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0234-5 · Cited by 114
Eckle, T. D. L. G., Kewley, E. M., Brodsky, K. S., Tak, E., Bonney, S. K., Gobel, M., Anderson, D. E., Glover, L. E., Riegel, A. K., Colgan, S. P., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1100593 · Cited by 113
Self-citationSalman, S., Meyers, D. J., Wicks, E. E., Lee, S. N., Datan, E., Thomas, A. M., Anders, N. M., Hwang, Y., Lyu, Y., Yang, Y., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci156774 · Cited by 111 · cited 4×
“Thus, based on its similarity in gene target induction to acriflavine, 32-134D was recently identified as a nonspecific HIF inhibitor with a chemical structure unrelated to that of acriflavine 59 .”
InfluentialKeely, S., Campbell, E. L., Baird, A. W., Hansbro, P. M., Shalwitz, R. A., Kotsakis, A., McNamee, E. N., Eltzschig, H. K., Kominsky, D., & Colgan, S. P. (2013) · Mucosal Immunology · doi:10.1038/mi.2013.29 · Cited by 111
Self-citationHyvärinen, J., Hassinen, I. E., Sormunen, R. T., Mäki, J. M., Kivirikko, K. I., Koivunen, P., & Myllyharju, J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.084855 · Cited by 110
Schejbel, L., Skattum, L., Hagelberg, S., Åhlin, A., Schiller, B., Berg, S., Genel, F., Truedsson, L., & Garred, P. (2011) · Genes and Immunity · doi:10.1038/gene.2011.39 · Cited by 109
Nucleotide Metabolism and Cell-Cell Interactions
Eltzschig, H. K., Weissmüller, T., Mager, A., & Eckle, T. D. L. G. (2006) · Humana Press eBooks · doi:10.1385/1-59745-113-4:73 · Cited by 108
Self-citationHypoxic and Pharmacological Activation of HIF Inhibits SARS-CoV-2 Infection of Lung Epithelial Cells
Wing, P. A. C., Keeley, T. P., Zhuang, X., Lee, Y. S., Prange‐Barczynska, M., Tsukuda, S., Morgan, S. B., Harding, A. C., Argles, I. L. A., Kurlekar, S., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2021.109020 · Cited by 108
Erythrocytosis and Pulmonary Hypertension in a Mouse Model of Human HIF2A Gain of Function Mutation
Tan, Q., Kerestes, H., Percy, M. J., Pietrofesa, R. A., Chen, L., Khurana, T. S., Christofidou‐Solomidou, M., Lappin, T. R. J., & Lee, F. S. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.444059 · Cited by 104
Labrousse-Arias, D., Castillo‐González, R., Rogers, N. M., Torres‐Capelli, M., Barreira, B., Aragonés, J., Cogolludo, A. L., Isenberg, J. S., & Calzada, M. J. (2015) · Cardiovascular Research · doi:10.1093/cvr/cvv243 · Cited by 103
Bao, W., Qin, P., Needle, S., Erickson‐Miller, C. L., Duffy, K. J., Ariazi, J. L., Zhao, S., Olzinski, A. R., Behm, D. J., Pipes, G. C. T., et al. (2010) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e3181e2bfef · Cited by 102
Hirota, S. A., Fines, K., Ng, J., Traboulsi, D., Lee, J., Ihara, E., Li, Y., Willmore, W. G., Chung, D. C., Scully, M. M., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.03.045 · Cited by 100
Macdougall, I. C., Roger, S. D., de Francisco, A., Goldsmith, D. J. A., Schellekens, H., Ebbers, H. C., JELKMANN, W. E. B., London, G. M., Casadevall, N., Hörl, W. H., et al. (2012) · Kidney International · doi:10.1038/ki.2011.500 · Cited by 100
Eckle, T. D. L. G., Hughes, K., Ehrentraut, H., Brodsky, K. S., Rosenberger, P., Choi, D., Ravid, K., Weng, T., Xia, Y., Blackburn, M. R., et al. (2013) · The FASEB Journal · doi:10.1096/fj.13-228551 · Cited by 99
Self-citation
Research works printed but not linked: 2
- Pelosci, A. LITESPARK-005 trial reveals PFS benefit of belzutifan in advanced RCC. Cancer Network, Home of the Journal ONCOLOGY (23 August 2023).
- Tang, H. et al. Endothelial HIF-2alpha contributes to severe pulmonary hypertension due to endothelial-to-mesenchymal transition. Am. J. Physiol. Lung Cell Mol. Physiol. 314, L256–L275 (2018).
Cited by
Sorted by citations
Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches
Tufail, M., Jiang, C., & Li, N. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02280-1 · Cited by 454
Glaviano, A., Lau, H., Carter, L. M., Lee, E. H. C., Lam, H. Y., Okina, E., Tan, D. J. J., Tan, W., Ang, H. L., Carbone, D., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01634-6 · Cited by 169
Zhang, J., Yao, M., Xia, S., Zeng, F., & Liu, Q. (2025) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-024-00682-7 · Cited by 150
Reactive oxygen species (ROS) in cancer: from mechanism to therapeutic implications
Akter, S., Madhuvilakku, R., Kar, A. K., Nila, I. S., Liu, P., Inuzuka, H., Wei, W., & Hong, Y. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02583-x · Cited by 135
Jin, Y., Wu, O., Chen, Q., Chen, L., Zhang, Z., Tian, H., Zhou, H., Zhang, K., Gao, J., Wang, X., et al. (2024) · Advanced Science · doi:10.1002/advs.202404275 · Cited by 82
Metadata
- Authors
- Yuan, X., Ruan, W., Bobrow, B., Carmeliet, P., & Eltzschig, H. K.
- Affiliations
- The University of Texas Health Science Center at Houston (US)
- Central South University (CN)
- Khalifa University of Science and Technology (AE)
- Outcomes Research Consortium (US)
- Corresponding author
- Yuan, Xiaoyi
- Eltzschig, Holger K.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2023-12-20
- Volume
- 23
- Issue
- 3
- Pages
- 175-200
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- PMC
- PMC12337356
- OpenAlex
- W4390038502
- Cited by
- 245
- References
- 317
- Citations by year
- 2026: 100 · 2025: 96 · 2024: 48 · 2023: 1
- FWCI
- 7.73
- Type
- journal article
- Language
- en
- Open access
- green
- pure.au.dk
- Licence
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Lirias (submittedVersion, other-oa)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- U.S. Department of Defense (W81XWH2110032)
- Akebia Therapeutics
- National Institutes of Health
- National Heart, Lung, and Blood Institute (R01HL154720, R01HL165748, R01HL169519, R01HL155950)
- National Institute of General Medical Sciences (T32GM135118)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK122796)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Keywords
- hypoxia-inducible factor, HIF stabilization, HIF activation, HIF inhibition, oxygen sensing, erythropoiesis, ischemia, inflammation, cancer therapy, retinal neovascularization, pulmonary hypertension, pharmacological targeting, adverse effects
- MeSH terms
- Hypoxia, Humans, Neoplasms, Oxygen, Transcription Factors, Basic Helix-Loop-Helix Transcription Factors, Basic Helix-Loop-Helix Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
